A Randomised Double Blind (Sponsor Unblinded), Single and Repeat Ascending Dose First Time in Human Study in Healthy Subjects, Cold Urticaria and Chronic Spontaneous Urticaria Subjects to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2017
At a glance
- Drugs GSK 2646264 (Primary)
- Indications Urticaria
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 17 Aug 2017 Planned End Date changed from 31 Jul 2017 to 31 Oct 2017.
- 17 Aug 2017 Planned primary completion date changed from 1 May 2017 to 31 Oct 2017.
- 27 Apr 2017 Planned End Date changed from 1 Jun 2017 to 31 Jul 2017.